20.91
4.81%
0.96
Dopo l'orario di chiusura:
20.91
Precedente Chiudi:
$19.95
Aprire:
$19.82
Volume 24 ore:
93,173
Relative Volume:
1.16
Capitalizzazione di mercato:
$873.57M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+1.55%
1M Prestazione:
+11.16%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Nome
Zenas Biopharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Zenas Bio: Recent IPO With Late-Stage Candidate (NASDAQ:ZBIO) - Seeking Alpha
Zenas started at buy by four banks on lead drug potential (NASDAQ:ZBIO) - Seeking Alpha
Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab - Investing.com Canada
Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum - Investing.com Canada
Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials - Investing.com Canada
Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials - Investing.com Canada
Biopharma financings surge to $86.2B in 2024, with $8.7B in September - BioWorld Online
Halda appoints new chief executive - The Pharma Letter
IgG4-related Disease Market to Show Remarkable Growth Trends - openPR
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
Zenas BioPharma CEO acquires $360k worth of company shares - Investing.com India
Zenas BioPharma CEO acquires $360k worth of company shares By Investing.com - Investing.com South Africa
Zenas BioPharma’s $225 Million IPO - Global Legal Chronicle
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - The Korea Bizwire
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase ... - The Bakersfield Californian
Zenas BioPharma Announces Closing of Full Exercise of - GlobeNewswire
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in - EIN News
Upstream Bio goes public amid spate of IPOs - The Pharma Letter
Zenas BioPharma sees $15 million in stock purchases by Zebra Aggregator - Investing.com South Africa
Zenas BioPharma director acquires $999k in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director acquires $999k in company stock - Investing.com Canada
IPOs, GLP-1 vs. PD-1, and AI in biotech: a BioCentury podcast - BioCentury
Zenas BioPharma director buys $7.48m in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director buys $7.48m in company stock - Investing.com
Zenas BioPharma director Jason Raleigh acquires $15 million in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director Jason Raleigh acquires $15 million in company stock - Investing.com India
Fairmount Healthcare Fund II L.P. buys $5.1m of Zenas BioPharma stock - Investing.com India
SR One Capital management buys $38m of Zenas BioPharma stock - Investing.com Australia
MBX, Zenas And Bicara IPOs Generate Big First Day Returns, But Will They Last? - Scrip
Biotech IPO Shares Climb in Trading Debuts After Deals Upsized - MSN
Biotech IPO Shares Climb in Trading Debuts After Deals Upsized | Stock Market News - Mint
Biotech IPOs Surge on Debut: Upsized Deals Boost Shares for Drug Developers Tackling Autoimmune Diseases - Share Price India News
Trio of first-day pops may bode well for biotech IPO window - BioCentury
Biotech Startups Make Pre-Election Sprint to the Public Markets - The Wall Street Journal
2 Life Sciences Cos. Start Trading After Raising $540M Total - Law360
Biotech trio revives the IPO market - Axios
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - MedCity News
Shares of two Mass. biotech IPOs rise on first day of trading - The Business Journals
Zenas Biopharma Inc Azioni (ZBIO) Dati Finanziari
Non sono disponibili dati finanziari per Zenas Biopharma Inc (ZBIO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Zenas Biopharma Inc Azioni (ZBIO) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
ENRIGHT PATRICK G | Director |
Sep 16 '24 |
Buy |
17.00 |
440,000 |
7,480,000 |
774,530 |
Nunn Jason Raleigh | Director |
Sep 16 '24 |
Buy |
17.00 |
882,352 |
14,999,984 |
1,946,564 |
Fairmount Funds Management LLC | Director |
Sep 16 '24 |
Buy |
17.00 |
300,000 |
5,100,000 |
1,604,891 |
SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
2,235,294 |
37,999,998 |
1,946,564 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):